PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia
详细信息 查看全文
- 作者：Pranav Guptaa ; Rishil J. Kathawalaa ; Liuya Weia ; b ; Fang Wangc ; XiaoKun Wangc ; Brian J. Drukerd ; Li-Wu Fuc ; fulw@mail.sysu.edu.cn" class="auth_mail" title="E-mail the corresponding author ; Zhe-Sheng Chena ; chenz@stjohns.edu" class="auth_mail" title="E-mail the corresponding author
- 关键词：PBA2 ; Chronic myeloid leukemia ; BCR-ABL ; T315I ; Resistance
- 刊名：Cancer Letters
- 出版年：2016
- 出版时间：28 December 2016
- 年：2016
- 卷：383
- 期：2
- 页码：220-229
- 全文大小：1794 K
文摘
- •
PBA2 is a modern inhibitor of the imatinib-resistant BCR-ABL T315I mutation.
- •
PBA2 potently inhibits the BCR-ABL signaling pathway and mRNA expression of BCR-ABL.
- •
PBA2 induces sub G1 phase and early apoptosis with subsequent increase in ROS production.
- •
PBA2 is a suitable drug candidate for the treatment against the T315I mutation in CML.